Erratum: Acute myocardial infarction (The Lancet (2017) 389(10065) (197–210) (S0140673616306778) (10.1016/S0140-6736(16)30677-8));Acute myocardial infarction

The Lancet

Volumn 389, Issue 10065, 2017, Pages 197-210

  Reed, Grant W ^a   Rossi, Jeffrey E ^a   Cannon, Christopher P ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BIVALIRUDIN; CANGRELOR; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; PRASUGREL; TICAGRELOR; TIROFIBAN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BARE METAL STENT; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; DRUG ELUTING STENT; ELECTROCARDIOGRAPHY; FIBRINOLYSIS; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; ROUTINE ASPIRATION THROMBECTOMY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; TREATMENT DURATION; VASCULAR ACCESS; FIBRINOLYTIC THERAPY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PROCEDURES; TRENDS;

ANTICOAGULANTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; THROMBOLYTIC THERAPY;

EID: 84995676332     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30007-7     Document Type: Erratum

References (141)

1. 1 Nichols, M, Townsend, N, Scarborough, P, Rayner, M, Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 35 (2014), 2950–2959.
2. 2 Yeh, RW, Sidney, S, Chandra, M, Sorel, M, Selby, JV, Go, AS, Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362 (2010), 2155–2165.
3. 3 Weintraub, WS, Daniels, SR, Burke, LE, et al. the American Heart Association Advocacy Coordinating Committee the Council on Cardiovascular Disease in the Young the Council on the Kidney in Cardiovascular Disease the Council on Epidemiology and Prevention the Council on Cardiovascular Nursing the Council on Arteriosclerosis the Thrombosis and Vascular Biology the Council on Clinical Cardiology, Stroke Council. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation 124 (2011), 967–990.
4. 4 O'Gara, PT, Kushner, FG, Ascheim, DD, et al., the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127 (2013), e362–e425.
5. 5 Thygesen, K, Alpert, JS, Jaffe, AS, et al. the Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction the Authors/Task Force Members Chairpersons the Biomarker Subcommittee the ECG Subcommittee the Imaging Subcommittee the Classification Subcommittee the Intervention Subcommittee the Trials & Registries Subcommittee the Trials & Registries Subcommittee the Trials & Registries Subcommittee the Trials & Registries Subcommittee the ESC Committee for Practice Guidelines (CPG), the Document Reviewers. Third universal definition of myocardial infarction. J Am Coll Cardiol 60 (2012), 1581–1598.
6. 6 Libby, P, Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 368 (2013), 2004–2013.
7. 7 Stone, NJ, Robinson, JG, Lichtenstein, AH, et al., the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:suppl 2 (2014), S1–45.
8. 8 Morrow, DA, Cannon, CP, Jesse, RL, et al., the National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115 (2007), e356–e375.
9. 9 Roffi, M, Patrono, C, Collet, JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 267–315.
10. 10 Jneid, H, Anderson, JL, Wright, RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 60 (2012), 645–681.
11. 11 de Araújo Gonçalves, P, Ferreira, J, Aguiar, C, Seabra-Gomes, R, TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 26 (2005), 865–872.
12. 12 Kumar, A, Cannon, CP, Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc 84 (2009), 917–938.
13. 13 Cannon, CP, Weintraub, WS, Demopoulos, LA, et al., the TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)—Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001), 1879–1887.
14. 14 Montalescot, G, Cayla, G, Collet, JP, et al., the ABOARD Investigators. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA 302 (2009), 947–954.
15. 15 Steg, PG, James, SK, Atar, D, et al., the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33 (2012), 2569–2619.
16. 16 Windecker, S, Kolh, P, Alfonso, F, et al., the Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
17. 17 Amsterdam, EA, Wenger, NK, Brindis, RG, et al. the American College of Cardiology the American Heart Association Task Force on Practice Guidelines the Society for Cardiovascular Angiography and Interventions the Society of Thoracic Surgeons, the American Association for Clinical Chemistry. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e139–e228.
18. 18 Cannon, CP, Gibson, CM, Lambrew, CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 283 (2000), 2941–2947.
19. 19 Widimský, P, Budesínský, T, Vorác, D, et al., the ‘PRAGUE’ Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial—PRAGUE-2. Eur Heart J 24 (2003), 94–104.
20. 20 Andersen, HR, Nielsen, TT, Rasmussen, K, et al., the DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349 (2003), 733–742.
21. 21 Busk, M, Maeng, M, Rasmussen, K, et al., the DANAMI-2 Investigators. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. Eur Heart J 29 (2008), 1259–1266.
22. 22 Nordmann, AJ, Hengstler, P, Harr, T, Young, J, Bucher, HC, Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Am J Med 116 (2004), 253–262.
23. 23 Zhu, MM, Feit, A, Chadow, H, Alam, M, Kwan, T, Clark, LT, Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 88 (2001), 297–301.
24. 24 Pasceri, V, Patti, G, Speciale, G, Pristipino, C, Richichi, G, Di Sciascio, G, Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 153 (2007), 749–754.
25. 25 Kastrati, A, Dibra, A, Spaulding, C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28 (2007), 2706–2713.
26. 26 De Luca, G, Stone, GW, Suryapranata, H, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol 133 (2009), 213–222.
27. 27 Menichelli, M, Parma, A, Pucci, E, et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 49 (2007), 1924–1930.
28. 28 Moses, JW, Leon, MB, Popma, JJ, et al., the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003), 1315–1323.
29. 29 Spaulding, C, Henry, P, Teiger, E, et al., the TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006), 1093–1104.
30. 30 Jolly, SS, Cairns, JA, Yusuf, S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372 (2015), 1389–1398.
31. 31 Frobert, O, Lagerqvist, B, Olivecrona, GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 369 (2013), 1587–1597.
32. 32 Kumbhani, DJ, Cannon, CP, Fonarow, GC, et al., the Get With the Guidelines Steering Committee and Investigators. Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. JAMA 302 (2009), 2207–2213.
33. 33 Badheka, AO, Patel, NJ, Grover, P, et al. Impact of annual operator and institutional volume on percutaneous coronary intervention outcomes: a 5-year United States experience (2005–2009). Circulation 130 (2014), 1392–1406.
34. 34 Levine, GN, Bates, ER, Blankenship, JC, et al. the American College of Cardiology Foundation the American Heart Association Task Force on Practice Guidelines, the Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–122.
35. 35 Jang, JS, Jin, HY, Seo, JS, et al. The transradial versus the transfemoral approach for primary percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis. EuroIntervention 8 (2012), 501–510.
36. 36 Joyal, D, Bertrand, OF, Rinfret, S, Shimony, A, Eisenberg, MJ, Meta-analysis of ten trials on the effectiveness of the radial versus the femoral approach in primary percutaneous coronary intervention. Am J Cardiol 109 (2012), 813–818.
37. 37 Mamas, MA, Ratib, K, Routledge, H, et al. Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. Heart 98 (2012), 303–311.
38. 38 Valgimigli, M, Gagnor, A, Calabró, P, et al., the MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet 385 (2015), 2465–2476.
39. 39 The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993), 673–682.
40. 40 Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994), 311–322.
41. 41 TIMI Study Group. The Thrombolysis in Myocardial Infarction: Phase I findings. N Engl J Med 312 (1985), 932–936.
42. 42 French, JK, Hyde, TA, Patel, H, et al. Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. J Am Coll Cardiol 34 (1999), 62–69.
43. 43 Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence, International Joint Efficacy Comparison of Thrombolytics. Lancet 346 (1995), 329–336.
44. 44 Keeley, EC, Boura, JA, Grines, CL, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003), 13–20.
45. 45 Pinto, DS, Kirtane, AJ, Nallamothu, BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 114 (2006), 2019–2025.
46. 46 Boersma, E, the Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 27 (2006), 779–788.
47. 47 The Global Use of Strategies to Open Occluded Coronary Arteries: A comparison of reteplase with alteplase for acute myocardial infarction. (GUSTO III) Investigators. N Engl J Med 337 (1997), 1118–1123.
48. 48 Van De Werf, F, Adgey, J, Ardissino, D, et al., the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354 (1999), 716–722.
49. 49 Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 (2006), 569–578.
50. 50 Zalewski, J, Bogaerts, K, Desmet, W, et al. Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. J Am Coll Cardiol 57 (2011), 1867–1873.
51. 51 Ellis, SG, Tendera, M, de Belder, MA, et al., the FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358 (2008), 2205–2217.
52. 52 Armstrong, PW, Gershlick, AH, Goldstein, P, et al., the STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 368 (2013), 1379–1387.
53. 53 Collet, JP, Montalescot, G, Le May, M, Borentain, M, Gershlick, A, Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol 48 (2006), 1326–1335.
54. 54 Cantor, WJ, Fitchett, D, Borgundvaag, B, et al., the TRANSFER-AMI Trial Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 360 (2009), 2705–2718.
55. 55 Di Mario, C, Dudek, D, Piscione, F, et al., the CARESS-in-AMI (Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction) Investigators. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 371 (2008), 559–568.
56. 56 Hochman, JS, Lamas, GA, Buller, CE, et al., the Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 355 (2006), 2395–2407.
57. 57 Menon, V, Ruzyllo, W, Carvalho, AC, et al. Infarct artery distribution and clinical outcomes in occluded artery trial subjects presenting with non-ST-segment elevation myocardial infarction (from the long-term follow-up of Occluded Artery Trial [OAT]). Am J Cardiol 111 (2013), 930–935.
58. 58 Steg, PG, Thuaire, C, Himbert, D, et al., the DECOPI Investigators. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J 25 (2004), 2187–2194.
59. 59 Dzavík, V, Buller, CE, Lamas, GA, et al., the TOSCA-2 Investigators. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation 114 (2006), 2449–2457.
60. 60 Levine, GN, Bates, ER, Blankenship, JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol 67 (2016), 1235–1250.
61. 61 Wald, DS, Morris, JK, Wald, NJ, et al., the PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 369 (2013), 1115–1123.
62. 62 Gershlick, AH, Khan, JN, Kelly, DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 65 (2015), 963–972.
63. 63 Engstrøm, T, Kelbæk, H, Helqvist, S, et al., the DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 386 (2015), 665–671.
64. 64 Farkouh, ME, Domanski, M, Sleeper, LA, et al., the FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367 (2012), 2375–2384.
65. 65 Mohr, FW, Morice, MC, Kappetein, AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381 (2013), 629–638.
66. 66 Hillis, LD, Smith, PK, Anderson, JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124 (2011), 2610–2642.
67. 67 Mehta, SR, Granger, CB, Boden, WE, et al., the TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 360 (2009), 2165–2175.
68. 68 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336 (1990), 827–830.
69. 69 Cairns, JA, Gent, M, Singer, J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313 (1985), 1369–1375.
70. 70 Yusuf, S, Zhao, F, Mehta, SR, Chrolavicius, S, Tognoni, G, Fox, KK, the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
71. 71 Mehta, SR, Bassand, JP, Chrolavicius, S, et al., the CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363 (2010), 930–942.
72. 72 Chen, ZM, Jiang, LX, Chen, YP, et al., the COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005), 1607–1621.
73. 73 Sabatine, MS, Cannon, CP, Gibson, CM, et al., the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005), 1179–1189.
74. 74 Patti, G, Colonna, G, Pasceri, V, Pepe, LL, Montinaro, A, Di Sciascio, G, Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005), 2099–2106.
75. 75 Gurbel, PA, Erlinge, D, Ohman, EM, et al., the TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308 (2012), 1785–1794.
76. 76 Wiviott, SD, Braunwald, E, McCabe, CH, et al., the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
77. 77 Roe, MT, Armstrong, PW, Fox, KA, et al., the TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367 (2012), 1297–1309.
78. 78 Montalescot, G, Bolognese, L, Dudek, D, et al., the ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369 (2013), 999–1010.
79. 79 Montalescot, G, Collet, JP, Ecollan, P, et al., the ACCOAST Investigators. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. J Am Coll Cardiol 64 (2014), 2563–2571.
80. 80 Wallentin, L, Becker, RC, Budaj, A, et al., the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
81. 81 Montalescot, G, van 't Hof, AW, Lapostolle, F, et al., the ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371 (2014), 1016–1027.
82. 82 Hansson, EC, Jidéus, L, Åberg, B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J 37 (2016), 189–197.
83. 83 Parodi, G, Xanthopoulou, I, Bellandi, B, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol 65 (2015), 511–512.
84. 84 Rollini, F, Franchi, F, Hu, J, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol 67 (2016), 1994–2004.
85. 85 Harrington, RA, Stone, GW, McNulty, S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361 (2009), 2318–2329.
86. 86 Bhatt, DL, Lincoff, AM, Gibson, CM, et al., the CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361 (2009), 2330–2341.
87. 87 Bhatt, DL, Stone, GW, Mahaffey, KW, et al., the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368 (2013), 1303–1313.
88. 88 Steinhubl, SR, Berger, PB, Mann, JT 3rd, et al., the CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002), 2411–2420.
89. 89 Park, SJ, Park, DW, Kim, YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362 (2010), 1374–1382.
90. 90 Collet, JP, Silvain, J, Barthélémy, O, et al., the ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384 (2014), 1577–1585.
91. 91 Feres, F, Costa, RA, Abizaid, A, et al., the OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
92. 92 Valgimigli, M, Campo, G, Monti, M, et al., the Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125 (2012), 2015–2026.
93. 93 Mauri, L, Kereiakes, DJ, Yeh, RW, et al., the DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
94. 94 Yeh, RW, Kereiakes, DJ, Steg, PG, et al., the DAPT Study Investigators. Benefits and risks of extended duration dual antiplatelet therapy After PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 65 (2015), 2211–2221.
95. 95 Bonaca, MP, Bhatt, DL, Cohen, M, et al., the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
96. 96 Yeh, RW, Secemsky, EA, Kereiakes, DJ, et al., the DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315 (2016), 1735–1749.
97. 97 Sabate, M, Cequier, A, Iñiguez, A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 380 (2012), 1482–1490.
98. 98 Sarno, G, Lagerqvist, B, Nilsson, J, et al. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol 64 (2014), 16–24.
99. 99 de la Torre Hernández, JM, Tejedor, P, Camarero, TG, et al. Early healing assessment with optical coherence tomography of everolimus-eluting stents with bioabsorbable polymer (synergy™) at 3 and 6 months after implantation. Catheter Cardiovasc Interv, 2015 published online Nov, 3. http://dx.doi.org/10.1002/ccd.26299.
100. 100 Dewilde, WJ, Oirbans, T, Verheugt, FW, et al., the WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
101. 101 Bhatt, DL, Cryer, BL, Contant, CF, et al., the COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363 (2010), 1909–1917.
102. 102 Van't Hof, AW, Ten Berg, J, Heestermans, T, et al., the Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372 (2008), 537–546.
103. 103 Mehilli, J, Kastrati, A, Schulz, S, et al., the Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119 (2009), 1933–1940.
104. 104 Oler, A, Whooley, MA, Oler, J, Grady, D, Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 276 (1996), 811–815.
105. 105 Antman, EM, McCabe, CH, Gurfinkel, EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100 (1999), 1593–1601.
106. 106 Goodman, SG, Cohen, M, Bigonzi, F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 36 (2000), 693–698.
107. 107 Montalescot, G, Zeymer, U, Silvain, J, et al., the ATOLL Investigators. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 378 (2011), 693–703.
108. 108 Gibson, CM, Murphy, SA, Montalescot, G, et al., the ExTRACT-TIMI 25 Investigators. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49 (2007), 2238–2246.
109. 109 Yusuf, S, Mehta, SR, Chrolavicius, S, et al., the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006), 1464–1476.
110. 110 Yusuf, S, Mehta, SR, Chrolavicius, S, et al., the OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006), 1519–1530.
111. 111 Cavender, MA, Sabatine, MS, Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 384 (2014), 599–606.
112. 112 Stone, GW, McLaurin, BT, Cox, DA, et al., the ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006), 2203–2216.
113. 113 Kastrati, A, Neumann, FJ, Schulz, S, et al., the ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 365 (2011), 1980–1989.
114. 114 Stone, GW, Mehran, R, Goldstein, P, et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. J Am Coll Cardiol 65 (2015), 27–38.
115. 115 Steg, PG, van 't Hof, A, Hamm, CW, et al., the EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 369 (2013), 2207–2217.
116. 116 Shahzad, A, Kemp, I, Mars, C, et al., the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 384 (2014), 1849–1858.
117. 117 Han, Y, Guo, J, Zheng, Y, et al., the BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 313 (2015), 1336–1346.
118. 118 Valgimigli, M, Frigoli, E, Leonardi, S, et al., the MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 373 (2015), 997–1009.
119. 119 Cutlip, DE, Kereiakes, DJ, Mauri, L, Stoler, R, Dauerman, HL, the EDUCATE Investigators. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. JACC Cardiovasc Interv 8 (2015), 404–410.
120. 120 Mega, JL, Braunwald, E, Wiviott, SD, et al., the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366 (2012), 9–19.
121. 121 Morrow, DA, Braunwald, E, Bonaca, MP, et al., the TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366 (2012), 1404–1413.
122. 122 Schwartz, GG, Olsson, AG, Ezekowitz, MD, et al., the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001), 1711–1718.
123. 123 de Lemos, JA, Blazing, MA, Wiviott, SD, et al., the Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004), 1307–1316.
124. 124 Cannon, CP, Braunwald, E, McCabe, CH, et al., the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
125. 125 Grundy, SM, Cleeman, JI, Merz, CN, et al. the National Heart Lung, and Blood Institute the American College of Cardiology Foundation, the American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004), 227–239.
126. 126 Reiner, Z, Catapano, AL, De Backer, G, et al. the European Association for Cardiovascular Prevention & Rehabilitation, the ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32 (2011), 1769–1818.
127. 127 Lloyd-Jones, DM, Morris, PB, Ballantyne, CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 68 (2016), 92–125.
128. 128 Cannon, CP, Blazing, MA, Giugliano, RP, et al., the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
129. 129 Buxton, AE, Lee, KL, Fisher, JD, Josephson, ME, Prystowsky, EN, Hafley, G, the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 (1999), 1882–1890.
130. 130 Moss, AJ, Hall, WJ, Cannom, DS, et al., the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335 (1996), 1933–1940.
131. 131 Moss, AJ, Zareba, W, Hall, WJ, et al., the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002), 877–883.
132. 132 Bardy, GH, Lee, KL, Mark, DB, et al., the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005), 225–237.
133. 133 Epstein, AE, DiMarco, JP, Ellenbogen, KA, et al. the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) the American Association for Thoracic Surgery, the Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 117 (2008), e350–e408.
134. 134 Perk, J, De Backer, G, Gohlke, H, et al. the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), the ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33 (2012), 1635–1701.
135. 135 Chen, ZM, Pan, HC, Chen, YP, et al., the COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005), 1622–1632.
136. 136 Roberts, R, Rogers, WJ, Mueller, HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83 (1991), 422–437.
137. 137 Pfeffer, MA, Braunwald, E, Moyé, LA, et al., the The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992), 669–677.
138. 138 Fox, KM, the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003), 782–788.
139. 139 McMurray, JJ, Packer, M, Desai, AS, et al., the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
140. 140 Pitt, B, Remme, W, Zannad, F, et al., the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003), 1309–1321.
141. 141 Pitt, B, Zannad, F, Remme, WJ, et al., the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999), 709–717.